Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
International Urology and Nephrology
Erschienen in: International Urology and Nephrology 9/2016

02.06.2016 | Urology - Review

Cardiovascular risk after androgen deprivation therapy for prostate cancer: an Asian perspective

verfasst von: Jeremy Yuen Chun Teoh, Chi-Fai Ng

Erschienen in: International Urology and Nephrology | Ausgabe 9/2016

Einloggen, um Zugang zu erhalten

Abstract

Androgen deprivation therapy (ADT) plays an important role in managing prostate cancer. However, ADT may result in major cardiovascular events and potentially lead to fatal consequences. Cardiovascular disease is the leading cause of mortality and it is a very important health condition to look into. Asians and Caucasians differ both physiologically and genetically, and they may have display different cardiovascular profiles. In this article, we reviewed the literature focusing on the cardiovascular risk after ADT for prostate cancer in the Asian population. We would discuss about the pathogenesis of ADT leading to cardiovascular events, summarize the findings concerning cardiac and stroke risks after ADT, compare between the different modalities of ADT and also provide genetic basics which are unique to Asians. We hope this article would provide more insights into the cardiovascular risk after ADT for prostate cancer in an Asian perspective.
Literatur
1.
Huggins C, Hodges CV (2002) Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 168:9–12CrossRefPubMed
2.
Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G et al (2006) Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7:472–479CrossRefPubMed
3.
Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO et al (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360:103–106CrossRefPubMed
4.
Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G et al (1997) Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337:295–300CrossRefPubMed
5.
D’Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW (2004) 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292:821–827CrossRefPubMed
6.
Sharifi N, Gulley JL, Dahut WL (2005) Androgen deprivation therapy for prostate cancer. JAMA 294:238–244CrossRefPubMed
7.
Hellerstedt BA, Pienta KJ (2002) The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 52:154–179CrossRefPubMed
8.
Keating NL, O’Malley AJ, Smith MR (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24:4448–4456CrossRefPubMed
9.
Lage MJ, Barber BL, Markus RA (2007) Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer. Urology 70:1104–1108CrossRefPubMed
10.
Lopez AM, Pena MA, Hernandez R, Val F, Martin B, Riancho JA (2005) Fracture risk in patients with prostate cancer on androgen deprivation therapy. Osteoporos Int 16:707–711CrossRefPubMed
11.
Azoulay L, Yin H, Benayoun S, Renoux C, Boivin JF, Suissa S (2011) Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer. Eur Urol 60:1244–1250CrossRefPubMed
12.
Ohira T, Iso H (2013) Cardiovascular disease epidemiology in Asia: an overview. Circ J 77:1646–1652CrossRefPubMed
13.
Collins L, Mohammed N, Ahmad T, Basaria S (2012) Androgen deprivation therapy for prostate cancer: implications for cardiometabolic clinical care. J Endocrinol Invest 35:332–339PubMed
14.
Saylor PJ, Smith MR (2009) Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 181:1998–2006 (discussion 7–8) CrossRefPubMedPubMedCentral
15.
Traish AM, Saad F, Guay A (2009) The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl 30:23–32CrossRefPubMed
16.
Scragg JL, Jones RD, Channer KS, Jones TH, Peers C (2004) Testosterone is a potent inhibitor of L-type Ca(2+) channels. Biochem Biophys Res Commun 318:503–506CrossRefPubMed
17.
Malkin CJ, Pugh PJ, Morris PD, Kerry KE, Jones RD, Jones TH et al (2004) Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 90:871–876CrossRefPubMedPubMedCentral
18.
Dong F, Skinner DC, Wu TJ, Ren J (2011) The heart: a novel gonadotrophin-releasing hormone target. J Neuroendocrinol 23:456–463CrossRefPubMed
19.
Radu A, Pichon C, Camparo P, Antoine M, Allory Y, Couvelard A et al (2010) Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med 363:1621–1630CrossRefPubMed
20.
Albertsen PC, Klotz L, Tombal B, Grady J, Olesen TK, Nilsson J (2014) Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol 65:565–573CrossRefPubMed
21.
Teoh JY, Chan SY, Chiu PK, Poon DM, Cheung HY, Hou SS et al (2015) Risk of acute myocardial infarction after androgen-deprivation therapy for prostate cancer in a Chinese population. BJU Int 116:382–387CrossRefPubMed
22.
Teoh JY, Chiu PK, Chan SY, Mak VM, Poon DM, Cheung HY et al (2016) Androgen deprivation therapy and the risk of acute myocardial infarction in Chinese men with prostate cancer. BJU Int 117(Suppl 1):2
23.
Huang G, Yeung CY, Lee KK, Liu J, Ho KL, Yiu MK et al (2014) Androgen deprivation therapy and cardiovascular risk in chinese patients with nonmetastatic carcinoma of prostate. J Oncol 2014:529468CrossRefPubMedPubMedCentral
24.
Akaza H (2010) Future prospects for luteinizing hormone-releasing hormone analogues in prostate cancer treatment. Pharmacology 85:110–120CrossRefPubMed
25.
Wang LH, Liu CK, Chen CH, Kao LT, Lin HC, Huang CY (2016) No increased risk of coronary heart disease for patients receiving androgen deprivation therapy for prostate cancer in Chinese/Taiwanese men. Andrology 4:128–132CrossRefPubMed
26.
Teoh JY, Chiu PK, Chan SY, Poon DM, Cheung HY, Hou SS et al (2015) Risk of ischemic stroke after androgen deprivation therapy for prostate cancer in the Chinese population living in Hong Kong. Jpn J Clin Oncol 45:483–487CrossRefPubMed
27.
Chung SD, Chen YK, Wu FJ, Lin HC (2012) Hormone therapy for prostate cancer and the risk of stroke: a 5-year follow-up study. BJU Int 109:1001–1005CrossRefPubMed
28.
Van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, Bill-Axelson A et al (2010) Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. J Clin Oncol 28:3448–3456CrossRefPubMed
29.
Jespersen CG, Norgaard M, Borre M (2014) Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol 65:704–709CrossRefPubMed
30.
Keating NL, O’Malley AJ, Freedland SJ, Smith MR (2010) Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 102:39–46CrossRefPubMedPubMedCentral
31.
Gandaglia G, Sun M, Popa I, Schiffmann J, Abdollah F, Trinh QD et al (2014) The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study. BJU Int 114:E82–E89CrossRefPubMed
32.
Teoh JY, Chan SY, Chiu PK, Poon DM, Cheung HY, Hou SS et al (2015) Risk of cardiovascular thrombotic events after surgical castration versus gonadotropin-releasing hormone agonists in Chinese men with prostate cancer. Asian J Androl 17:493–496PubMed
33.
Zaitsu M, Yamanoi M, Mikami K, Takeshima Y, Okamoto N, Imao S et al (2012) Surgical castration in hormone-refractory metastatic prostate cancer patients can be an alternative for medical castration. Adv Urol 2012:979154CrossRefPubMed
34.
Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P et al (2008) The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 102:1531–1538CrossRefPubMed
35.
Ozono S, Ueda T, Hoshi S, Yamaguchi A, Maeda H, Fukuyama Y et al (2012) The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer. Jpn J Clin Oncol 42:477–484CrossRefPubMed
36.
You D, Chung BH, Lee SE, Kim CS (2015) Efficacy and safety of degarelix in Korean patients with prostate cancer requiring androgen deprivation therapy: Open-label multicenter phase III study. Prostate Int 3:22–26CrossRefPubMedPubMedCentral
37.
Li J, Mercer E, Gou X, Lu YJ (2013) Ethnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes. Am J Cancer Res 3:127–151PubMedPubMedCentral
38.
Hsing AW, Gao YT, Wu G, Wang X, Deng J, Chen YL et al (2000) Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Res 60:5111–5116PubMed
39.
Stanford JL, Just JJ, Gibbs M, Wicklund KG, Neal CL, Blumenstein BA et al (1997) Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res 57:1194–1198PubMed
40.
Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Dahl D, Brufsky A et al (1997) The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A 94:3320–3323CrossRefPubMedPubMedCentral
41.
Mohlig M, Arafat AM, Osterhoff MA, Isken F, Weickert MO, Spranger J et al (2011) Androgen receptor CAG repeat length polymorphism modifies the impact of testosterone on insulin sensitivity in men. Eur J Endocrinol 164:1013–1018CrossRefPubMed
42.
Nadeau G, Bellemare J, Audet-Walsh E, Flageole C, Huang SP, Bao BY et al (2011) Deletions of the androgen-metabolizing UGT2B genes have an effect on circulating steroid levels and biochemical recurrence after radical prostatectomy in localized prostate cancer. J Clin Endocrinol Metab 96:E1550–E1557CrossRefPubMed
Metadaten
Titel
Cardiovascular risk after androgen deprivation therapy for prostate cancer: an Asian perspective
verfasst von
Jeremy Yuen Chun Teoh
Chi-Fai Ng
Publikationsdatum
02.06.2016
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 9/2016
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-016-1337-5

Weitere Artikel der Ausgabe 9/2016

International Urology and Nephrology 9/2016 Zur Ausgabe

Nephrology – Review

The importance of success prediction in angioaccess surgery

Urology - Original Paper

Midline lesions of the prostate: role of MRI/TRUS fusion biopsy and implications in Gleason risk stratification

Urology - Original Paper

BDNF-ERK1/2 signaling pathway in ketamine-associated lower urinary tract symptoms

Urology - Original Paper

Salvage cryotherapy with third-generation technology for locally recurrent prostate cancer after radiation therapy

Nephrology – Original Paper

Chlorhexidine for routine PD catheter exit-site care

Urology - Original Paper

Relationship of serum levels and dietary intake of isoflavone, and the novel bacterium Slackia sp. strain NATTS with the risk of prostate cancer: a case–control study among Japanese men

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise